Kerry Group Plc — Board/Management Information 2023

Oct 26, 2023

National Storage Mechanism | Additional information

RNS Number : 3141R

Kerry Group PLC

26 October 2023

26 October 2023

LEI: 635400TLVVBNXLFHWC59

KERRY GROUP PLC

Regulatory Announcement

DIRECTORATE CHANGE

Kerry Group plc ("Kerry" and the "Group") is pleased to announce the appointment of Professor Catherine Godson as a non-executive director with effect from 1 November 2023. 

Prof. Godson has an international reputation in scientific research gained during a long and successful academic career in the US, Switzerland and at University College Dublin ("UCD"), during which time she held a variety of senior management roles including Vice President, Innovation. She is currently Director, Diabetes Complications Research Centre at the UCD Conway Institute and UCD School of Medicine. Prof. Godson has a broad knowledge across human health and is a global expert on diabetes as well as cardiovascular and kidney diseases.

Prof. Godson is the Associate Dean, Research and Innovation at UCD School of Medicine and currently serves on the Irish Research Council and as a Trustee of Barts Charity, London.

Prof. Godson has notified Kerry Group plc that there are no matters requiring disclosure in relation to Rule 6.1.66 (1) to (6) of the Euronext Dublin Listing Rules and under LR 9.6.13 (1) to (6) of the UK FCA Listing Rules.

Commenting on Prof. Godson's appointment, Kerry Group plc Chairman, Tom Moran said: "On behalf of the Group, we welcome Catherine's appointment to the Board, and we look forward to leveraging her extensive biomedical research and biotechnology knowledge as the Group advances its positioning in the nutrition sector particularly in the area of human health and emerging technologies".

	CONTACT INFORMATION
	Group Secretary
	Ronan Deasy
	+353 66 7182000 | ronan.deasy@kerry.ie
	Website
	www.kerry.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFEIFMIEDSEDS